Establishment of transplantable porcine tumor cell lines derived from MHC-inbred miniature swine

Blood

Volumn 110, Issue 12, 2007, Pages 3996-4004

  Cho, Patricia S ^a,b   Lo, Diana P ^a   Wikiel, Krzysztof J ^a,b   Rowland, Haley C ^a   Coburn, Rebecca C ^a   McMorrow, Isabel M ^a,b   Goodrich, Jennifer G ^a   Arn, J Scott ^a   Billiter, Robert A ^a   Houser, Stuart L ^a   Shimizu, Akira ^a   Yang, Yong Guang ^a,b   Sachs, David H ^a,b   Huang, Christene A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ARTICLE; AUTOPSY; CANCER CELL CULTURE; CANCER GROWTH; CANCER TRANSPLANTATION; CARCINOMA; CLINICAL FEATURE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HAPLOTYPE; IMMUNE DEFICIENCY; IMMUNE STATUS; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LYMPHADENOPATHY; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SWINE; TISSUE CULTURE; WHOLE BODY RADIATION;

EID: 35948963666     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-02-074450     Document Type: Article

References (57)

1. Adelman CA, Petrini JH, Attwooll CL. Modeling disease in the mouse: lessons from DNA damage response and cell cycle control genes. J Cell Biochem. 2006;97:459-473.
2. Braithwaite AW, Royds JA, Jackson P. The p53 story: layers of complexity. Carcinogenesis. 2005;26:1161-1169.
3. Decker S, Sausville EA. Preclinical modeling of combination treatments: fantasy or requirement? Ann N Y Acad Sci. 2005;1059:61-69.
4. Egorov IK. Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape. Cancer Immunol Immunother. 2006;55:1-22.
5. Gutmann DH, Hunter-Schaedle K, Shannon KM. Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest. 2006;116:847-852.
6. Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother. 2006;55:96-103.
7. Casal M, Haskins M. Large animal models and gene therapy. Eur J Human Genetics. 2006;14:266-272.
8. Frazier ME, Ushijima RN, Andrews TK, Hooper MJ. Comparative studies on cell lines established from normal and radiation-exposed miniature swine. In Vitro. 1979;15:1001-1012.
9. Howard EB. Experimental induction of porcine leukemia. Bibl Haematol. 1970;430-439.
10. Ahrar K, Madoff DC, Gupta S, et al. Development of a large animal model for lung tumors. J Vasc Interv Radiol. 2002;13:923-928.
11. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med. 1988;168:2391-2396.
12. Pelot MR, Pearson DA, Swenson K, et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant. 1999;5:133-143.
13. Mapara MY, Kim YM, Wang SP, et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 2002;100:1903-1909.
14. Cina RA, Wikiel KJ, Lee PW, et al. Stable multilineage chimerism without graft versus host disease following nonmyeloablative haploidentical hematopoietic cell transplantation. Transplantation. 2006;81:1677-1685.
15. Mezrich JD, Haller GW, Arn JS, et al. Histocompatible miniature swine: an inbred large-animal model. Transplantation. 2003;75:904-907.
16. Sachs DH, Leight G, Cone J, et al. Transplantation in miniature swine: I, fixation of the major histocompatibility complex. Transplantation. 1976;22:559-567.
17. Sachs DH. MHC homozygous miniature swine. In: Swindle MM, Moody DC, Phillips LD, eds. Swine as Models in Biomedical Research. Ames, IA: Iowa State University Press; 1992:3-15.
18. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1985. NIH publication no. 86-23.
19. Pescovitz MD, Book BK, Aasted B, et al. Analyses of monoclonal antibodies reacting with porcine CD3: results from the Second International Swine CD Workshop. Vet Immunol Immunopathol. 1998;60:261-268.
20. Pescovitz MD, Book BK, Aasted B, et al. Summary of workshop findings for antibodies reacting with porcine T-cells and activation antigens: results from the Second International Swine CD Workshop. Vet Immunol Immunopathol. 1998;60:251-260.
21. Kim YB, Zhang J, Davis WC, Lunney JK. CD11/ CD18 panel report for swine CD workshop. Vet Immunol Immunopathol. 1994;43:289-291.
22. Pescovitz MD, Lunney JK, Sachs DH. Preparation and characterization of monoclonal antibodies reactive with porcine PBL. J Immunol. 1984;133:368-375.
23. Hammerberg C, Schurig GG. Characterization of monoclonal antibodies directed against swine leukocytes. Vet Immunol Immunopathol. 1986;11:107-121.
24. Pescovitz MD, Aasted B, Canals A, et al. Analysis of monoclonal antibodies reactive with the porcine CD2 antigen. Vet Immunol Immunopathol. 1994;43:229-232.
25. Huang CA, Lorf T, Arn JS, et al. Characterization of a monoclonal anti-porcine CD3 antibody. Xenotransplant. 1999;5:201-212.
26. Saalmuller A, Denham S, Haverson K, et al. The Second International Swine CD Workshop. Vet Immunol Immunopathol. 1996;54:155-158.
27. Saalmuller A, Aasted B, Canals A, et al. Analyses of mAb reactive with porcine CD8. Vet Immunol Immunopathol. 1994;43:249-254.
28. Heinz M, Huang CA, Emery DW, et al. Use of CD9 expression to enrich for porcine hematopoietic progenitors. Exp Hematol. 2002;30:809-815.
29. Denham S, Zwart RJ, Whittall JT, et al. Monoclonal antibodies putatively identifying porcine B cells. Vet Immunol Immunopathol. 1998;60:317-328.
30. Boersma WJ, Zwart RJ, Sinkora J, et al. Summary of workshop findings for porcine B-cell markers. Vet Immunol Immunopathol. 2001;80:63-78.
31. Sinkora J, Rehakova Z, Haverson K, et al. Monoclonal antibodies putatively recognising activation and differentiation antigens. Vet Immunol Immunopathol. 2001;80:143-164.
32. Paul PS, van Deusen RA, Mengeling WL. Monoclonal precipitating antibodies to porcine immunoglobulin M. Vet Immunol Immunopathol. 1985;8:311-328.
33. Sinkora J, Rehakova Z, Samankova L, et al. Characterization of monoclonal antibodies recognizing immunoglobulin kappa and lambda chains in pigs by flow cytometry. Vet Immunol Immunopathol. 2001;80:79-91.
34. Huang CA, Fuchimoto Y, Scheier-Dolberg R, et al. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model. J Clin Invest. 2000;105:173-181.
35. Huang CA, Fuchimoto Y, Gleit ZL, et al. Posttransplant lymphoproliferative disease in miniature swine after allogeneic hematopoietic cell transplantation: similarity to human PTLD and association with a porcine gammaherpesvirus. Blood. 2001;97:1467-1473.
36. Cho PS, Meuller NJ, Cameron AM, et al. Risk factors for the development of post-transplant lymphoproliferative disorder in a large animal model. Am J Transplantation. 2004;4:1274-1282.
37. Dor FJ, Doucette KE, Mueller NJ, et al. Posttransplant lymphoproliferative disease after allogeneic transplantation of the spleen in miniature swine. Transplantation. 2004;78:286-291.
38. Diehl V, Kirchner HH, Burrichter H, et al. Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep. 1982;66:615-632.
39. Matsuo Y, Drexler HG. Establishment and characterization of human B cell precursor-leukemia cell lines. Leuk Res. 1998;22:567-579.
40. Drexler HG, Matsuo AY, MacLeod RA. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk Res. 2000;24:881-911.
41. Drexler HG, Minowada J. History and classification of human leukemia-lymphoma cell lines. Leuk Lymphoma. 1998;31:305-316.
42. Benson JD, Chen YN, Cornell-Kennon SA, et al. Validating cancer drug targets. Nature. 2006;441:451-456.
43. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930-942.
44. Wollman SH. Summary of observations on transplantable tumors of the rat thyroid gland. Biochimie. 1999;81:409-412.
45. Looney WB, Mayo AA, Kovacs CJ, et al. Solid tumor models for the assessment of different treatment modalities: II, rapid, intermediate, and slow growing transplantable rat hepatomas. Life Sci. 1976;18:377-389.
46. Yang TJ. Immunobiology of a spontaneously regressive tumor, the canine transmissible venereal sarcoma (review). Anticancer Res. 1988;8:93-95.
47. Sanford BH. Some observations on an induced adaptation in a transplantable tumor. Exp Cell Res. 1965;39:97-102.
48. Sanford B, McKhann CF. Tumor immunity. Transplant Proc. 1977;9:1307-1309.
49. Sanford BH, Codington JF, Jeanloz RW, Palmer PD. Transplantability and antigenicity of two sublines of the TA3 tumor. J Immunol. 1973;110:1233-1237.
50. Sanford BH, Codington JF. Further studies on the effect of neuraminidase on tumor cell transplantability. Tissue Antigens. 1971;1:153-161.
51. Hughes RC, Sanford B, Jeanloz RW. Regeneration of the surface glycoproteins of a transplantable mouse tumor cell after treatment with neuraminidase. Proc Natl Acad Sci U S A. 1972;69:942-945.
52. Hughes RC, Palmer PD, Sanford BH. Factors involved in the cytotoxicity of normal guinea pig serum for cells of murine tumor TA3 sublines treated with neuraminidase. J Immunol. 1973;111:1071-1080.
53. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196-206.
54. Hagmar B, Ryd W, Erkell LJ. Methods in metastasis research: a critical review. Invasion Metastasis. 1983;3:1-21.
55. Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer. 2004;40:852-857.
56. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis. 2005;26:513-523.
57. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1998;17:279-284.